News | August 10, 2008

Flexible Stenting Solutions Completes First Human Study of New Peripheral Arterial Stent

August 11, 2008 - Flexible Stenting Solutions Inc. said today a physician at Auckland City Hospital in New Zealand successfully implanted several of its third generation arterial stents for the treatment of peripheral vascular lesions involving the superficial femoral and popliteal arteries.

Patients with lesion lengths up to 100 mm and fully occluded lesions were included in the study.

This first-in-man clinical trial using a full range of stent sizes, including 120 mm, was performed by Associate Professor Andrew Holden who is the director of interventional radiology at Auckland City Hospital, and the principal investigator.

“The flexible stent handled both stenoses and occlusions in the femoro-popliteal artery segment as well as I had hoped with excellent immediate appearances following deployment” Holden said. “Overall, I felt the stent and delivery system performed very well in the acute phase and I await the longer term follow up in these patients with great interest.”

Flexible Stenting Solutions has developed a novel, self-expanding stent technology to provide a wide range of vascular and non-vascular therapies. The treatment of femoro-popliteal disease is the first vascular application of Flexible Stenting Solutions’ technology.

While stent procedures have become widespread in the treatment of coronary arterial disease, their use in the more challenging peripheral vascular disease setting had been limited in the last several years by inadequate stent design, the company said. The fully connected SFA/Pop flexible stent has coupled technology with clinical needs by reportedly providing a highly durable and fatigue resistant stent with superior radial stiffness and low chronic outward force.

For more information: www.flexiblestent.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init